Centre for Drug Design and Discovery
Overview
Centre for Drug Design and Discovery is a Belgium-based investment fund and drug discovery center that invests in and supports the translation of academic and biotech biomedical research into new medicines.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Endlyz Therapeutics | Mar 2026 | Seed | Co-investor |
| Rewind Therapeutics | Jan 2023 | Series A Extension | Co-investor |
| Enedra Therapeutics | May 2025 | VC Round | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Centre for Drug Design and Discovery based?
Centre for Drug Design and Discovery is headquartered in Leuven, Belgium.
When was Centre for Drug Design and Discovery founded?
Centre for Drug Design and Discovery was founded in 2006.
How many portfolio companies does Centre for Drug Design and Discovery have?
Centre for Drug Design and Discovery has 3 portfolio companies in Caplight's dataset.
What are some companies in Centre for Drug Design and Discovery's portfolio?
Portfolio companies visible on Caplight include Endlyz Therapeutics, Rewind Therapeutics, Enedra Therapeutics.
What was Centre for Drug Design and Discovery's most recent investment shown here?
Centre for Drug Design and Discovery's most recent investment in this portfolio sample was in Endlyz Therapeutics in 2026.
What sectors does Centre for Drug Design and Discovery focus on?
Centre for Drug Design and Discovery focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Centre for Drug Design and Discovery focus on?
Centre for Drug Design and Discovery typically invests at the Early stage.
What is Centre for Drug Design and Discovery's AUM?
Centre for Drug Design and Discovery's assets under management are estimated between $165.3M and $165.3M.